AnaCardio is a privately held Swedish clinical-stage biopharmaceutical company founded in 2017 and based on research from Karolinska Institutet. Its lead candidate, AC01, is a first-in-class oral ghrelin receptor agonist designed to enhance cardiac contractility without the adverse effects typical of conventional inotropes. The company reported positive results from an initial study showing safety, target engagement, and improved contractility. Funds from the recent financing will support completion of the phase 1b/2a GOAL-HF1 study, including a 28-day cohort expansion planned for early 2025. Management positions the data and funding as enabling advancement to proof-of-concept and progression toward late-stage clinical development. AnaCardio AB is a Swedish clinical-stage biopharmaceutical company focused on developing novel therapies for heart failure. Its lead asset, AC01, is being developed for patients with heart failure and reduced ejection fraction (HFrEF). The company plans a clinical phase 1b/2a study of AC01 in HFrEF patients, expected to begin at selected centers in several European countries in fall/winter 2022. Proceeds from the recent financing will fund that planned study. AnaCardio was founded on research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The company frames heart failure as a potentially fatal disease and the most common cause of hospitalization. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure based on research from Karolinska Institutet. Its lead asset, AC01, targets improved contractility of the heart muscle through a unique and differentiated mechanism. The company completed a fundraising to progress clinical development and is preparing to start a phase 1b/2a study with AC01 in 2022. The new capital enables AnaCardio to complete those preparations and advance its clinical plans. Karolinska Development is a strategic investor and has direct ownership interest amounting to 21 percent. The financing structure and participation signal continued backing from the Nordic life-sciences ecosystem.

Total raised

$38M

Funding rounds

3

Latest round

Series A

Latest activity

Jan 2025